Compare FIHL & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIHL | WGS |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | 1300 |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2015 | N/A |
| Metric | FIHL | WGS |
|---|---|---|
| Price | $18.53 | $88.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $22.36 | ★ $140.71 |
| AVG Volume (30 Days) | 437.7K | ★ 710.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.34 | $29.98 |
| Revenue Next Year | $7.05 | $24.85 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $55.17 |
| 52 Week High | $20.50 | $170.87 |
| Indicator | FIHL | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 49.00 |
| Support Level | $18.56 | $78.80 |
| Resistance Level | $19.05 | $95.94 |
| Average True Range (ATR) | 0.53 | 5.76 |
| MACD | -0.13 | 1.35 |
| Stochastic Oscillator | 21.93 | 80.83 |
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.